R&D | December 07, 2025
Bayer advances fight against rare kidney disease with new experimental drug
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Subscribe To Our Newsletter & Stay Updated
